Drug candidate is one of several oncology assets approaching or in clinical development, discovered through Oxford ...

Boehringer Ingelheim has breathed life into an American Lung Association campaign, providing support for a new push to educate people with bronchiectasis about how to better manage the disease.

What happens when data projects forget the people who use them? A Disconnect. Boehringer Ingelheim turned things around by ...

Oxford BioTherapeutics Announces Third Oncology Drug Candidate from Boehringer Ingelheim Collaboration Selected to Advance into IND-Enabling Studies Provided by GlobeNewswire Jul 3, 2025, 12:00:00 AM ...

Results come after positive results from a trial among people with idiopathic pulmomary disease.

The OBT-Boehringer partnership began in 2013 and has expanded through subsequent agreements in 2020 and 2022 to include additional programs. The collaboration has yielded multiple development-stage ...

Joshua K. Sabari, MD, of NYU Langone Health discusses promising results for zongertinib in HER2-mutant NSCLC; the tyrosine ...

Boehringer Ingelheim Greece, alongside its partners, is addressing this issue with the 'Sailboat for Health' initiative. This floating medical facility embarks on annual voyages to deliver ...